Springworks Therapeutics Stock Alpha and Beta Analysis
| SWTX Stock | USD 54.14 0.11 0.20% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as SpringWorks Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in SpringWorks Therapeutics over a specified time horizon. Remember, high SpringWorks Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to SpringWorks Therapeutics' market risk premium analysis include:
Beta 0.17 | Alpha 0.68 | Risk 6.05 | Sharpe Ratio 0.1 | Expected Return 0.62 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
SpringWorks |
SpringWorks Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. SpringWorks Therapeutics market risk premium is the additional return an investor will receive from holding SpringWorks Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in SpringWorks Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate SpringWorks Therapeutics' performance over market.| α | 0.68 | β | 0.17 |
SpringWorks Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of SpringWorks Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how SpringWorks Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.SpringWorks Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how SpringWorks Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading SpringWorks Therapeutics shares will generate the highest return on investment. By understating and applying SpringWorks Therapeutics stock market price indicators, traders can identify SpringWorks Therapeutics position entry and exit signals to maximize returns.
SpringWorks Therapeutics Return and Market Media
The median price of SpringWorks Therapeutics for the period between Fri, Nov 29, 2024 and Thu, Feb 27, 2025 is 38.69 with a coefficient of variation of 18.31. The daily time series for the period is distributed with a sample standard deviation of 7.6, arithmetic mean of 41.5, and mean deviation of 5.64. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 4192 shares by Badreddin Edris of SpringWorks Therapeutics at 40.6219 subject to Rule 16b-3 | 11/29/2024 |
2 | Disposition of 8034 shares by Badreddin Edris of SpringWorks Therapeutics at 42.2447 subject to Rule 16b-3 | 12/03/2024 |
3 | Acquisition by Hambleton Julie of 12216 shares of SpringWorks Therapeutics at 44.77 subject to Rule 16b-3 | 12/17/2024 |
4 | Disposition of 3465 shares by Cassidy James of SpringWorks Therapeutics at 38.19 subject to Rule 16b-3 | 01/03/2025 |
5 | Disposition of 1658 shares by Cassidy James of SpringWorks Therapeutics at 38.86 subject to Rule 16b-3 | 01/06/2025 |
6 | Disposition of 3575 shares by Weinstein Herschel S of SpringWorks Therapeutics at 38.19 subject to Rule 16b-3 | 01/07/2025 |
7 | SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025 | 01/30/2025 |
8 | Disposition of 13186 shares by Islam Saqib of SpringWorks Therapeutics at 59.28 subject to Rule 16b-3 | 02/12/2025 |
9 | Insider Selling SpringWorks Therapeutics, Inc. Director Sells 175,000 Shares of Stock | 02/14/2025 |
10 | SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over | 02/19/2025 |
11 | SpringWorks Therapeutics Posts Earnings Results, Misses Estimates By 0.38 EPS | 02/20/2025 |
12 | SpringWorks Therapeutics Shares Gap Down Heres Why | 02/21/2025 |
About SpringWorks Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including SpringWorks or other stocks. Alpha measures the amount that position in SpringWorks Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 1.02 | 1.08 | Days Of Inventory On Hand | 297.0 | 282.15 |
SpringWorks Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of SpringWorks Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, SpringWorks Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of SpringWorks Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of SpringWorks Therapeutics. Please utilize our Beneish M Score to check the likelihood of SpringWorks Therapeutics' management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with SpringWorks Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for SpringWorks Stock Analysis
When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.